#USA #New York #Class Action #Securities Fraud #INOVIO Pharmaceuticals

Inovio Pharmaceuticals Under Fire: Class Action Securities Fraud Suit

In a significant developing story in the realm of biotechnology and corporate governance, investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) are currently faced with a class action securities lawsuit filed by the reputable law firm Levi & Korsinsky, LLP. This case has garnered attention due to claims of securities fraud that allegedly occurred between October 10, 2023, and December 26, 2025.

The lawsuit aims to recover losses for shareholders who may have been adversely affected by the company's alleged misleading public statements regarding its primary product development. Specifically, the complaint lodged against Inovio claims that the company made fraudulent assertions about its CELLECTRA device manufacturing processes and the regulatory approvals for its drug candidate, INO-3107.

Case Details

As laid out in the filed complaint, several egregious claims highlight the purported discrepancies between Inovio’s public statements and the actual state of affairs:
1. The manufacturing methods for Inovio's CELLECTRA device were purportedly deficient, raising red flags about the company's operational integrity.
2. There were unfavorable implications on their ability to submit the biologics license application (BLA) for their lead product candidate, INO-3107, by the anticipated deadline in the second half of 2024.
3. Inovio did not possess the requisite information to substantiate the eligibility of INO-3107 for FDA’s accelerated approval or priority review, leading to concerns about the viability of the product’s market prospects.
4. The overall regulatory and commercial potential of INO-3107 was allegedly overstated, which meant that investor confidence based on public statements was misplaced.

These allegations paint a concerning picture for investors who relied on the company’s guidance and public communications. The lawsuit thus positions a significant question mark over the credibility of Inovio Pharmaceuticals and its management.

Next Steps for Affected Investors

For shareholders affected by this situation, the deadline to take action is April 7, 2026. Interested parties are encouraged to contact Levi & Korsinsky for more information on how to participate in this litigation. Investors do not have to be lead plaintiffs to be eligible for compensation; they may still recover losses by simply being part of the class. Importantly, class members can seek recovery without incurring out-of-pocket costs or fees, diminishing the financial risks often associated with legal challenges.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built a robust reputation over the past 20 years, recovering hundreds of millions of dollars for shareholders in similar circumstances. Their expertise in complex securities litigation is evident, with a dedicated team specializing in representing investors. Their consistent ranking in ISS Securities Class Action Services' Top 50 Report as a leading securities litigation firm underscores their capability and success rate in high-stakes cases.

Contact Information

Investors seeking support or further information may reach out to Levi & Korsinsky’s legal team. You can contact Joseph E. Levi or Ed Korsinsky directly via email at [email protected] or by phone at (212) 363-7500. Their office is located at 33 Whitehall Street, 27th Floor, New York, NY 10004.

Conclusion

The allegations against Inovio Pharmaceuticals are severe, and the unfolding developments continue to intrigue stakeholders in the biotech industry. As the class action progresses, the implications for investor rights and corporate accountability will be closely watched by analysts and the public alike. If you believe you were affected by this situation, don't hesitate to reach out for your legal options before the deadline passes.